Aytu BioPharma Inc./$AYTU
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Aytu BioPharma Inc.
Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment. Its product portfolio includes EXXUA, ADHD Portfolio, Pediatric Portfolio, and Other. Majority of revenue comes from ADHD Portfolio. It has presence in United States.
- Ticker
- $AYTU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- Denver, United States
- Website
- aytubio.com
AYTU Metrics
BasicAdvanced
$20M
-
-$1.16
0.27
-
Price and volume
Market cap
$20M
Beta
0.27
52-week high
$3.07
52-week low
$1.75
Average daily volume
26K
Financial strength
Current ratio
1.13
Quick ratio
0.898
Long term debt to equity
0.282
Total debt to equity
0.513
Interest coverage (TTM)
-4.39%
Profitability
EBITDA (TTM)
-4.385
Gross margin (TTM)
63.95%
Net profit margin (TTM)
-24.76%
Operating margin (TTM)
-14.44%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
$760,000
Management effectiveness
Return on assets (TTM)
-4.54%
Return on equity (TTM)
-52.55%
Valuation
Price to revenue (TTM)
0.387
Price to book
0.55
Price to tangible book (TTM)
-3.17
Price to free cash flow (TTM)
6.856
Free cash flow yield (TTM)
14.58%
Free cash flow per share (TTM)
0.264
Growth
Revenue change (TTM)
-13.27%
Earnings per share change (TTM)
-46.43%
3-year revenue growth (CAGR)
-7.94%
10-year revenue growth (CAGR)
36.51%
3-year earnings per share growth (CAGR)
-39.03%
What the Analysts think about AYTU
Analyst ratings (Buy, Hold, Sell) for Aytu BioPharma Inc. stock.
Analyst projections of the future price of Aytu BioPharma Inc. stock.
AYTU Financial Performance
Revenues and expenses
AYTU Earnings Performance
Company profitability
Upcoming events
No upcoming events
AYTU News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.